Endothelial dysfunction is widely recognized as a precursor to a myriad of cardiovascular diseases, including atherosclerosis, hypertension, and thrombosis. Traditionally, its diagnosis involves systemic assessments or indirect markers that lack the spatial resolution to isolate dysfunction within individual microvessels. The inability to examine single capillaries in situ has led to a gap in understanding the localized pathophysiology and delayed therapeutic interventions.

The novel approach leverages optoacoustic mesoscopy, a hybrid imaging technology that exploits the photoacoustic effect, where pulsed laser light pulses induce ultrasound waves in tissues. This technique synergistically combines the contrast advantages of optical imaging with the spatial resolution of ultrasound, enabling visualization of vascular structures as small as single capillaries at unprecedented clarity. By tuning the optical excitation wavelengths, the system can distinctly capture the absorption characteristics of hemoglobin, allowing direct visualization of blood flow and oxygenation dynamics.

The research team led by He et al. meticulously designed a single-capillary imaging system that harnesses this technology to not only detect but also quantify endothelial dysfunction. This capability stems from the innovative scanning mechanisms and signal processing algorithms that enable the differentiation between healthy and dysfunctional endothelium based on changes in capillary morphology and hemodynamic parameters. The system’s sensitivity facilitates real-time monitoring, important for understanding the progression of vascular pathologies and evaluating therapeutic responses.

Crucially, the study demonstrates that optoacoustic mesoscopy can be used to resolve endothelial dysfunction without the need for invasive angiography or contrast dyes, which often pose risks to patients and are not suitable for repeated measures. This non-destructive approach preserves the native physiological environment, allowing longitudinal studies that track capillary health dynamically, an essential factor in chronic disease management and drug efficacy tests.

The implementation of this technology required overcoming substantial technical challenges, including optimizing laser pulse energy to ensure tissue safety while maintaining signal strength, enhancing detector sensitivity, and developing sophisticated computational models to reconstruct high-resolution, three-dimensional vascular images. These innovations collectively result in a system that achieves a striking balance between spatial resolution, penetration depth, and functional imaging capability.

The clinical implications of resolving endothelial dysfunction at such a granular level are profound. Early detection of microvascular impairments can facilitate preemptive therapeutic strategies, potentially mitigating the cascade of events leading to overt cardiovascular disease. Furthermore, this imaging modality could revolutionize the screening of diabetic retinopathy, peripheral artery disease, and other conditions where microvascular integrity is compromised.

Beyond diagnostics, optoacoustic mesoscopy offers a powerful investigative tool for fundamental vascular biology. Its capacity to visualize capillary networks and endothelial responses under various physiological and pathological conditions could illuminate mechanisms of vascular remodeling, angiogenesis, and inflammation. This could catalyze breakthroughs in understanding diseases characterized by microcirculatory dysfunction, ranging from cancer to neurodegenerative disorders.

The research also highlights the translational potential of optoacoustic mesoscopy into personalized medicine. By providing a detailed vascular map for individual patients, therapies can be tailored and adjusted based on real-time feedback, increasing efficacy and reducing adverse effects. This precision approach aligns with ongoing shifts toward integrating advanced imaging with genomics and biomarker analyses.

Importantly, this study stands as a testament to multidisciplinary collaboration, synthesizing expertise in photonics, engineering, computational modeling, and vascular biology. The resulting innovation exemplifies how convergent technologies can tackle entrenched biomedical challenges, yielding tools that were previously inconceivable.

While the reported system currently excels in controlled laboratory settings, ongoing efforts focus on enhancing portability and user-friendliness to facilitate clinical adoption. Integrating this system into clinical workflows could dramatically change how vascular health is monitored, offering a powerful adjunct or alternative to existing diagnostic modalities.

The scalability of optoacoustic mesoscopy also offers promising avenues for future research and applications. Enhancements in laser sources and detector arrays could expand the field of view, enabling simultaneous imaging of multiplexed vascular networks or the coupling with functional assays to assess endothelial cell signaling in real-time.

Moreover, the underlying technology’s flexibility allows adaptation to other biological tissues and disease models where high-resolution optical imaging is desirable. For instance, cancer researchers could exploit this modality to study tumor angiogenesis and its microenvironment, thereby tailoring anti-angiogenic therapies.

Contemplating the future, the convergence of optoacoustic mesoscopy with emerging artificial intelligence (AI) techniques is poised to further amplify its diagnostic power. Machine learning algorithms could automate image interpretation, detect subtle pathological changes, and predict outcomes based on vascular phenotypes, rendering this technology a linchpin in next-generation digital health platforms.

Critically, ethical considerations surrounding the widespread use of advanced imaging technologies must be addressed, including data privacy, equitable access, and ensuring that technological advancements translate into tangible health benefits rather than exacerbating disparities.

In summation, this research heralds a paradigm shift in vascular diagnostics and therapeutics. By elucidating endothelial dysfunction at the fundamental unit of microcirculation — the single capillary — optoacoustic mesoscopy opens unprecedented windows into vascular health. As the technology matures and proliferates, it promises to become an indispensable component of cardiovascular medicine and beyond, merging precision imaging with personalized care to improve patient outcomes on a global scale.

Subject of Research: Single-capillary endothelial dysfunction resolution and imaging using optoacoustic mesoscopy technology.

Article Title: Single-capillary endothelial dysfunction resolved by optoacoustic mesoscopy.

Article References:
He, H., Karlas, A., Fasoula, NA. et al. Single-capillary endothelial dysfunction resolved by optoacoustic mesoscopy. Light Sci Appl 15, 37 (2026). https://doi.org/10.1038/s41377-025-02103-6

Image Credits: AI Generated

DOI: 03 January 2026

Dr. Mehran, serving as Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai, has been a pivotal figure in the global cardiology community. Her work primarily focuses on devising novel randomized clinical trials and outcome research frameworks that ensure high standards of evidence-based practice. Her scientific influence extends through her prolific authorship of over 2,000 peer-reviewed articles, influencing clinical guidelines and therapeutic strategies for acute and chronic cardiovascular conditions.

One of the technical hallmarks of Dr. Mehran’s research resides in personalized cardiovascular medicine. She has been instrumental in developing validated individual risk scores that predict the probability of procedural complications such as bleeding and acute kidney injury. These risk stratification tools represent a vital advancement for tailoring therapeutic interventions to individual patient risk profiles, thereby improving procedural safety and optimizing overall clinical outcomes.

Her research methodology uniquely integrates large-scale, multicenter randomized trials with sophisticated outcome analytics, advancing the understanding of interventional procedures such as percutaneous coronary intervention (PCI). By meticulously examining factors that influence procedural success and patient recovery, her work enables clinicians to refine pre-procedural assessments and post-procedural management, mitigating complications and enhancing long-term cardiovascular health.

Dr. Mehran’s influence transcends individual clinical trials. She has played an essential role in shaping international cardiovascular practice guidelines through her consistent participation in guideline committees. Her contributions have fostered consensus on managing complex cardiovascular diseases, particularly in tailoring interventions based on risk stratification, which has been a foundational paradigm shift toward precision cardiovascular care.

Leadership is a recurring theme in Dr. Mehran’s career. She holds prominent roles including the vice presidency on the Board of Trustees at the American College of Cardiology (ACC) for 2025-2026 and serves as Chief Scientific Officer of the Cardiovascular Research Foundation (CRF). Through these influential platforms, she champions innovative research agendas and fosters collaborative networks that accelerate scientific discovery and clinical translation globally.

In addition to her robust academic and clinical research endeavors, Dr. Mehran has pioneered programs addressing gender disparities in cardiovascular medicine. She leads the Lancet Commission on Women’s Cardiovascular Diseases, an initiative mobilizing global expertise to elucidate sex-specific differences in cardiovascular physiology, disease progression, and therapeutic responses. This work aims to bridge critical knowledge gaps and promote equitable clinical trial representation.

Further advancing women’s cardiovascular health, Dr. Mehran directs the Women’s Heart and Vascular Center at Mount Sinai Fuster Heart Hospital. This center integrates multidisciplinary approaches catering exclusively to female patients’ unique pathophysiological and psychosocial cardiovascular risk factors. This integration exemplifies the transition toward specialized clinical pathways that acknowledge and address sex-specific cardiovascular manifestations.

Among her many accolades, Dr. Mehran has garnered numerous elite awards that signify her extensive impact on cardiology and medical science. Highlights include the 2016 American College of Cardiology’s Bernadine Healy Leadership Award, the 2019 European Society of Cardiology Silver Medal, the 2024 Icahn School of Medicine’s Jacobi Medallion, and notably, the 2025 ESC Gold Medal. These awards reflect both her scientific excellence and leadership in fostering research innovations.

Mount Sinai Health System, home to Dr. Mehran’s distinguished career, ranks among the world’s preeminent centers for cardiovascular care and research. The Mount Sinai Fuster Heart Hospital is nationally acclaimed, positioning second in the United States for cardiology and heart surgery according to U.S. News & World Report, and is recognized globally by Newsweek among the top specialized hospitals. This institutional excellence synergizes with Dr. Mehran’s work, creating an environment conducive to cutting-edge cardiovascular discoveries.

The recognition by the ESC not only celebrates Dr. Mehran’s individual achievements but also elevates the visibility of interventional cardiology’s evolving landscape. Interventional cardiology has rapidly progressed with advancements in device technology, procedural techniques, and perioperative pharmacotherapy, all areas where Dr. Mehran’s research has been influential. Her work has emphasized the seamless fusion of bench research with bedside applications, ensuring that innovative therapies translate into tangible clinical benefits.

This award highlights the pivotal role of mentorship and collaborative science in cardiovascular medicine. Dr. Mehran consistently emphasizes that such honors reflect the collective efforts of diverse teams, including junior investigators, clinical collaborators, and institutional support systems. Her commitment to nurturing the next generation ensures ongoing progress in a field that demands continuous innovation to combat the global burden of cardiovascular diseases.

The cardiovascular research community worldwide acknowledges that addressing the multifaceted challenges of cardiovascular disease requires dynamic leadership and interdisciplinary collaboration. Dr. Mehran’s career exemplifies this holistic approach, integrating clinical insights, methodical research, and advocacy for inclusivity and equity in medicine. The ESC Gold Medal serves as a beacon of scientific rigor, leadership, and dedication to patient-centered innovation in cardiovascular health.

As cardiovascular diseases remain a leading cause of global morbidity and mortality, the scientific contributions of thought leaders like Dr. Mehran are fundamental to improving outcomes. Her pioneering efforts in stratifying patient risk, refining interventional procedures, and addressing sex-specific disparities represent critical strides toward personalized cardiology and equitable healthcare. The broader impact of her work is undeniable in shaping the future landscape of cardiovascular medicine.

Subject of Research: Cardiovascular medicine, Interventional cardiology, Personalized risk assessment, Women’s cardiovascular health

Article Title: Dr. Roxana Mehran Awarded the European Society of Cardiology Gold Medal for Transformative Contributions to Cardiovascular Medicine

News Publication Date: August 29, 2025

Web References:

• https://mediasvc.eurekalert.org/Api/v1/Multimedia/4f02774c-7860-4824-909b-af93660b348d/Rendition/low-res/Content/Public
• https://www.mountsinai.org/
• https://www.escardio.org/

References: Not provided in original content

Image Credits: Mount Sinai Health System

Keywords: Cardiology, Cardiovascular disorders, Interventional cardiology, Clinical trials, Personalized medicine, Women’s cardiovascular health, Cardiovascular research, ESC Gold Medal

Coronary artery disease remains one of the foremost killers globally, driven largely by the formation of blood clots that obstruct the coronary arteries, depriving heart tissue of oxygen. Central to this disease process are platelets—tiny, anucleated blood cells responsible for clot formation. Antiplatelet therapies, including drugs like aspirin and P2Y12 inhibitors, are cornerstone treatments designed to disrupt platelet activation and aggregation. However, clinicians historically have faced challenges in accurately assessing how well a given therapy is working at the level of individual patients.

Traditional methods for evaluating platelet function tend to be indirect, cumbersome, or limited in their capacity to capture the complex morphology and behavioral heterogeneity of circulating platelets. This new study leverages state-of-the-art imaging technologies, combined with sophisticated computational algorithms, to comprehensively profile circulating platelets from patients undergoing antiplatelet therapy. By directly visualizing platelet characteristics and activity, this method provides unprecedented granularity into the efficacy of individualized treatments.

The research team, spearheaded by Hirose, Kodera, Nishikawa, and collaborators, utilized advanced microscopy coupled with deep-learning analytics to parse the intricate details of platelet morphology, granularity, and activation states. These parameters are essential because activated platelets undergo rapid shape changes, express specific surface markers, and aggregate more readily, all of which contribute to thrombosis. By painstakingly capturing and quantifying these features across thousands of platelets per patient, the team constructed a detailed "image-based platelet signature" that reflects the net effect of antiplatelet agents in vivo.

One of the key innovations in this study lies in its ability to bypass traditional surrogate markers and lab assays, moving directly to a phenotype-driven assessment. This phenotype-centric approach allows the researchers to detect subtle, clinically relevant differences between responders and non-responders to antiplatelet therapy, which could not be teased out by previous tests. Importantly, this may pave the way for dynamically adjusting drug dosage or switching therapies in near real-time, optimizing patient outcomes.

Moreover, the researchers demonstrated that this technology captures not only the static features of platelets at a snapshot in time but also offers temporal resolution, monitoring how platelet profiles evolve over the course of therapy. This dynamic profiling revealed that some patients experience transient resistance or fluctuating platelet reactivity, phenomena that have significant implications for risk stratification and treatment adherence monitoring.

The study cohort included CAD patients on various antiplatelet regimens, and the findings underscored marked heterogeneity in platelet responses that could not be predicted by genetic testing or standard hematological parameters alone. By correlating imaging-derived platelet signatures with clinical endpoints such as major adverse cardiovascular events, the team established the prognostic value of their profiling approach, spotlighting its potential utility in routine clinical practice.

Beyond prognostic implications, this technique opens new avenues for drug development. Pharmaceutical researchers can now utilize comprehensive platelet imaging to assess novel antiplatelet agents, enabling more nuanced mechanistic insights and facilitating the design of therapies that finely tune platelet activity without excessive bleeding risk—an ever-present challenge in balancing efficacy and safety.

Importantly, the image-based profiling method is also minimally invasive, requiring only small volumes of blood, and amenable to integration with existing clinical workflows. The authors envision that, with advances in automation and cost reduction, this platform could be adapted for widespread point-of-care use, transforming cardiovascular care from a one-size-fits-all approach to precision medicine.

The implications extend beyond coronary artery disease. Platelets play vital roles in a range of pathologies—including cerebrovascular disease, peripheral artery disease, and even cancer metastasis—so this imaging-based platform could serve as a versatile tool across multiple disciplines where platelet function is implicated.

Scientific experts have hailed this approach as a significant leap forward. Dr. Emily Carter, a leading thrombosis specialist not involved in the study, commented, “By harnessing the power of high-resolution imaging and machine learning, this study enables us to see the platelet as never before. It holds transformative potential for personalizing antiplatelet therapy, ultimately saving lives.”

The study authors are already advancing their work towards clinical trials aimed at validating the platform’s predictive power and integrating it into therapeutic decision-making algorithms. Additionally, efforts are underway to refine the computational models to identify even more subtle patterns, incorporating multimodal data such as genomics and proteomics to build a holistic understanding of platelet biology.

While promising, challenges remain. Standardizing sample preparation, ensuring reproducibility across diverse clinical settings, and scaling the technology economically are critical next steps. However, the foundational work laid out in this study provides a compelling blueprint for overcoming these hurdles.

In sum, the study by Hirose and colleagues represents a landmark in cardiovascular diagnostics. Their image-based platelet profiling does not merely offer a snapshot of platelet function; it provides a detailed narrative on how antiplatelet therapy modulates the platelet population at the individual level. This heralds a new era of precision cardiovascular medicine that could substantially reduce the burden of coronary artery disease globally.

As the field moves forward, integrating such technological innovations with existing therapeutic regimens promises to enhance efficacy, avoid adverse effects, and ultimately improve survival and quality of life for millions of patients worldwide. With continuous refinement and clinical validation, comprehensive image-based platelet profiling stands poised to become a new standard of care, illuminating the once elusive intricacies of platelet biology in health and disease.

Subject of Research: Direct evaluation of antiplatelet therapy effectiveness in coronary artery disease by comprehensive image-based profiling of circulating platelets.

Article Title: Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets.

Article References:
Hirose, K., Kodera, S., Nishikawa, M. et al. Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets. Nat Commun 16, 4386 (2025). https://doi.org/10.1038/s41467-025-59664-8

Image Credits: AI Generated